FDA · United States
natamycin — FDA regulatory status
natamycin (NATACYN) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.
Status snapshot
- Status
- FDA approved
- Brand
- NATACYN
- Mechanism
- Ergosterol sequestering agent
- Target
- Ergosterol
- Structured fields
- 6
Pharmacology context used for competitive intelligence: Ergosterol sequestering agent. Target: Ergosterol. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — FDA: approved.
Linked evidence on this spoke: 0 published clinical programs and 1 related patent record. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| FDA | United States | approved | — | Evidence |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 6844004 | Topical formulations of natamycin/pimaricin | US |
Related hubs
FAQ
What is the FDA approval status of natamycin?
natamycin currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get natamycin regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.